Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

96.96
+4.905.32%
Post-market: 97.200.2400+0.25%19:33 EDT
Volume:1.32M
Turnover:126.80M
Market Cap:24.36B
PE:-12.47
High:97.40
Open:92.45
Low:92.30
Close:92.06
52wk High:124.00
52wk Low:79.52
Shares:251.20M
Float Shares:109.00M
Volume Ratio:1.30
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7726
EPS(LYR):-5.5184
ROE:-9.30%
ROA:-5.41%
PB:1.22
PE(LYR):-17.57

Loading ...

OverviewCompanyNewsFilings

BioNTech CEO Ugur Sahin Disposes of $5,935,923 of Common Shares

Reuters
·
4 hours ago

BioNTech SE ADR Rises 5.3%, Outperforms Market

Dow Jones
·
4 hours ago

Sector Update: Healthcare

MT Newswires Live
·
7 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
9 hours ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

MT Newswires Live
·
Yesterday

Pharma Stocks Jump With Novavax up 12%, Moderna up 6%

Tiger Newspress
·
Yesterday

BofA Adjusts Price Target on BioNTech to $114 From $122, Keeps Buy Rating

MT Newswires Live
·
Yesterday

BioNTech price target lowered to $114 from $122 at BofA

TIPRANKS
·
Yesterday

Argus Research Initiates Coverage on BioNTech SE With Hold Rating

MT Newswires Live
·
Oct 08

BioNTech Se : Argus Research Initiates Coverage with Hold Rating

THOMSON REUTERS
·
Oct 08

BioNTech Price Target Cut to $114.00/Share from $115.00 by Morgan Stanley

Dow Jones
·
Oct 07

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Labcorp Holdings (LH) and Surgery Partners (SGRY)

TIPRANKS
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

BioNTech CEO Uğur Şahin Disposes of 93,000 Shares Worth $9,031,514.30

Reuters
·
Oct 07

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03
More